Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT00040950 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT00040950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00040950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2002
Completion date
October 31, 2007
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma